Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IM-1340

Antibody-drug conjugate · developed by Immunome

Phase 1 Most advanced trial
IMNM Developer
1 Registered trials

What is IM-1340?

IM-1340 is an antibody-drug conjugate, an antibody carrying a cytotoxic drug payload. It is studied in colorectal cancer, non-small cell lung cancer, small cell lung cancer and neuroendocrine neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Therapy area
Oncology
Developer
Immunome, Inc. (IMNM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07890246 Phase 1 Colorectal Cancer Not yet recruiting IMNM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CancerNeuroendocrine NeoplasmNon-Small Cell Lung CancerSmall Cell Lung Cancer

More from Immunome

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IMNM page.

Follow IMNM, the company behind IM-1340

See IMNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMNM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.